Inovio Pharmaceuticals (INO) Change in Receivables (2010 - 2025)
Inovio Pharmaceuticals (INO) posted Change in Receivables of $138278.0 for Q3 2025, up 129.43% sequentially from -$469925.0 in Q2 2025, and up 55.24% YoY from $89074.0 in Q3 2024.
Inovio Pharmaceuticals (INO) Change in Receivables (2010 - 2025) Analysis & Trends
Inovio Pharmaceuticals has reported Change in Receivables for 16 years, with the latest figure at $138278.0 in Q3 2025.
- Quarterly Change in Receivables rose 55.24% year-over-year to $138278.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$884149.0 (down 214.13% YoY) and the FY2024 annual result came in at -$1.2 million, up 87.08% from the prior year.
- Change in Receivables climbed to $138278.0 in Q3 2025 per INO's latest filing, from -$469925.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $3.9 million in Q2 2022 and troughed at -$8.8 million in Q1 2021.
- A 5-year average of -$951850.5 and a median of $81120.0 in 2023 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2021 and 2024: Change in Receivables tumbled 14969.06% in 2021, then soared 103.0% in 2024.
- Over 5 years, Change in Receivables stood at $906955.0 in 2021, then soared by 82.76% to $1.7 million in 2022, then tumbled by 84.25% to $261033.0 in 2023, then slumped by 354.25% to -$663683.0 in 2024, then surged by 120.83% to $138278.0 in 2025.
- According to Business Quant data, Change in Receivables over the past three periods registered $138278.0, -$469925.0, and $111181.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 138,278.00 |
| Sep 30, 2025 | 138,278.00 |
| Jun 30, 2025 | -469,925.00 |
| Jun 30, 2025 | -469,925.00 |
| Mar 31, 2025 | 111,181.00 |
| Mar 31, 2025 | 111,181.00 |
| Dec 31, 2024 | -663,683.00 |
| Dec 31, 2024 | -663,683.00 |
| Sep 30, 2024 | 89,074.00 |
| Sep 30, 2024 | 89,074.00 |
| Jun 30, 2024 | -777,417.00 |
| Jun 30, 2024 | -777,417.00 |
| Mar 31, 2024 | 145,854.00 |
| Mar 31, 2024 | 145,854.00 |
| Dec 31, 2023 | 261,033.00 |
| Dec 31, 2023 | 261,033.00 |
| Sep 30, 2023 | -2.97 Mn |
| Sep 30, 2023 | -2.97 Mn |
| Jun 30, 2023 | 81,120.00 |
| Jun 30, 2023 | 81,120.00 |